Top 5 Growth Stocks in Biotech

3. Ascendis Pharma A/S (NASDAQ:ASND)

Revenue Growth YOY: 557.93%

Headquartered in Hellerup, Denmark, Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical corporation. The company manufactures therapeutics to treat central nervous system disorders, endocrinology, growth hormone deficiency, diabetes, and infectious diseases. Ascendis Pharma A/S (NASDAQ:ASND) has developed Skytrofa, a medication for pediatric growth hormone deficiency. The company is also developing several other products for various adult and pediatric disorders, including TransCon hGH for growth hormone deficiency, TransCon PTH for adult hypoparathyroidism, and TransCon CNP for pediatric achondroplasia. Moreover, the pipeline also includes products for oncological disorders.

On February 16, 2023, the company announced its fourth quarter 2022 results. Revenue was reported at $24.44 million, exceeding market expectations by $4.22 million. Normalized EPS stood at $3.95, falling short of market estimates by $1.19.

As per Insider Monkey’s database, 33 hedge funds held stakes worth $2.3 billion in Ascendis Pharma A/S (NASDAQ:ASND) in Q4 2022, compared to 34 funds in the prior quarter with stakes worth $1.9 billion.